<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00887328</url>
  </required_header>
  <id_info>
    <org_study_id>NTA0901</org_study_id>
    <nct_id>NCT00887328</nct_id>
  </id_info>
  <brief_title>Extending the Time for Thrombolysis in Emergency Neurological Deficits</brief_title>
  <acronym>EXTEND</acronym>
  <official_title>Extending the Time for Thrombolysis in Emergency Neurological Deficits</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuroscience Trials Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Commonwealth Scientific and Industrial Research Organisation, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Melbourne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Melbourne Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Florey Institute of Neuroscience and Mental Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Neuroscience Trials Australia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary hypothesis being tested in this trial is that ischaemic stroke patients selected
      with significant penumbral mismatch (measured by MRI criteria) at 3 - 9 hours post onset of
      stroke will have improved clinical outcomes when given intravenous tissue plasminogen
      activator (tPA) compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rankin Scale (mRS) 0-1</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Categorical shift in modified Rankin Score (mRS)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ≥ 8 NIHSS points or reaching ≤ 1 on this scale</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death due to any cause</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic ICH</measure>
    <time_frame>24 hours</time_frame>
    <description>Symptomatic hemorrhage defined by SITS-MOST criteria: type 2 parenchymal hematoma associated with ≥4 point increase in NIHSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reperfusion</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recanalisation</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct growth</measure>
    <time_frame>24 hours</time_frame>
    <description>Difference in volumetric DWI volume between baseline and 24 hour MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent stroke</measure>
    <time_frame>3 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression (Montgomery-Asberg Depression Rating Scale [MADRS])</measure>
    <time_frame>3 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (Stroke Impact Scale)</measure>
    <time_frame>3 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>IV tPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous tissue plasminogen activator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tissue Plasminogen Activator (Alteplase)</intervention_name>
    <description>0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour</description>
    <arm_group_label>IV tPA</arm_group_label>
    <other_name>Actilyse</other_name>
    <other_name>Activase</other_name>
    <other_name>tPA</other_name>
    <other_name>r-tPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients presenting with hemispheric acute ischaemic stroke

          2. Patient, family member or legally responsible person depending on local ethics
             requirements has given informed consent

          3. Patient's age is ≥18 years

          4. Treatment onset can commence within ≥ 3 - 9 hours after stroke onset according to
             registered product information, or within 4.5 - 9 hours according to locally accepted
             guidelines*.

             (*Guidelines are currently under international review - advisory statement issued by
             the Stroke Council, American Heart Association and American Stroke Association)

          5. Patients who wake with stroke may be included if neurological and other exclusion
             criteria are satisfied. These 'wake up' strokes are defined as having no symptoms at
             sleep onset, but stroke symptoms on waking. The time of stroke onset is to be taken as
             the mid-point between sleep onset (or last known to be normal) and time of waking. The
             maximum time window for randomisation is then 9 hours from the mid-point as described.

          6. NIHSS score of ≥ 4 - 26 with clinical signs of hemispheric infarction.

          7. Penumbral mismatch - A &quot;hypo-perfusion to core&quot; volume ratio of greater than 1.2 and
             an absolute difference greater than 10mL (using a MR or CT Tmax &gt; 6 second delay)
             between perfusion lesion and MR-DWI or CT-CBF core lesion.

          8. An ischaemic core lesion volume of less than or equal to 70 ml using MR-DWI or CT-CBF
             ** Patients may be consented before or after penumbral screening depending upon local
             practice. The entire cohort of patients consented onto the study will be followed up
             with clinical assessments and biomarker studies regardless of eligibility for
             randomisation to treatment based on penumbral mismatch criteria

        Exclusion Criteria:

          1. Intracranial haemorrhage (ICH) identified by CT or MRI

          2. Rapidly improving symptoms, particularly if in the judgment of the managing clinician
             that the improvement is likely to result in the patient having an NIHSS score of &lt; 4
             at randomization

          3. Pre-stroke MRS score of ≥ 2 (indicating previous disability)

          4. Contra indication to imaging with MR with contrast agents

          5. Infarct core &gt;1/3 MCA territory qualitatively

          6. Participation in any investigational study in the previous 30 days

          7. Any terminal illness such that patient would not be expected to survive more than 1
             year

          8. Any condition that could impose hazards to the patient if study therapy is initiated
             or affect the participation of the patient in the study (this applies to patients with
             severe microangiopathy such as haemolytic uremic syndrome or thrombotic
             thrombocytopenic purpura). The judgment is left to the discretion of the Investigator.

          9. Pregnant women (clinically evident)

         10. Previous stroke within last three months

         11. Recent past history or clinical presentation of ICH, subarachnoid haemorrhage (SAH),
             arterio-venous (AV) malformation, aneurysm, or cerebral neoplasm. At the discretion of
             each Investigator.

         12. Current use of oral anticoagulants or a prolonged prothrombin time (INR &gt; 1.7) if the
             patient is on warfarin

         13. Use of heparin, except for low dose subcutaneous heparin, in the previous 48 hours and
             an activated prolonged partial thromboplastin time exceeding the upper limit of the
             local laboratory normal range.

         14. Use of glycoprotein IIb - IIIa inhibitors within the past 72 hours. Use of single or
             dual agent oral platelet inhibitors (clopidogrel and/or low-dose aspirin) prior to
             study entry is permitted.

         15. Clinically significant hypoglycaemia.

         16. Uncontrolled hypertension defined by a blood pressure &gt; 185 mmHg systolic or &gt;110 mmHg
             diastolic on at least 2 separate occasions at least 10 minutes apart, or requiring
             aggressive treatment to reduce the blood pressure to within these limits. The
             definition of &quot;aggressive treatment&quot; is left to the discretion of the responsible
             Investigator.

         17. Hereditary or acquired haemorrhagic diathesis

         18. Gastrointestinal or urinary bleeding within the preceding 21 days

         19. Major surgery within the preceding 14 days which poses risk in the opinion of the
             investigator.

         20. Exposure to a thrombolytic agent within the previous 72 hours

         21. Clinically deemed eligible for Endovascular Clot Retrieval (ECR) treatment by the
             treating team
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geoffrey Donnan, MD FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Florey Institute of Neuroscence and Mental Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Davis, MD FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Melbourne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michele Sallaberger</last_name>
    <phone>0438 471 423</phone>
    <email>michele.sallaberger@florey.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gosford Hospital</name>
      <address>
        <city>Kanwal</city>
        <state>New South Wales</state>
        <zip>2259</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jon Sturm</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark W Parsons, PhD FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Krause</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Romesh Markus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Neil Mahant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane &amp; Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephen Read</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gold Coast University Hospital</name>
      <address>
        <city>Gold Coast</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter Bailey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunshine Coast University Hospital</name>
      <address>
        <city>Nambour</city>
        <state>Queensland</state>
        <zip>4560</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rohan Grimley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Timothy Kleinig</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrew Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lyell McEwin Hospital</name>
      <address>
        <city>Elizabeth Vale</city>
        <state>South Australia</state>
        <zip>5112</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Deborah Field</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christopher Bladin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thanh Phan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western Hospital</name>
      <address>
        <city>Footscray</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tissa Wijeratne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Geelong Hospital</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ben Clissold, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Helen Dewey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephen M Davis, MD FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Epworth Healthcare</name>
      <address>
        <city>Richmond</city>
        <state>Victoria</state>
        <zip>3121</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Richard Gerraty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Blacker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Graeme Hankey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Turgut Tatlisumak</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Auckland Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1001</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alan Barber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Finland</country>
    <country>New Zealand</country>
  </location_countries>
  <link>
    <url>http://www.nsri.org.au</url>
    <description>National Stroke Research Institute</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2009</study_first_submitted>
  <study_first_submitted_qc>April 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2009</study_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ischemic stroke</keyword>
  <keyword>ischemic penumbra</keyword>
  <keyword>magnetic resonance imaging</keyword>
  <keyword>MRI</keyword>
  <keyword>diffusion imaging</keyword>
  <keyword>DWI</keyword>
  <keyword>perfusion imaging</keyword>
  <keyword>PWI</keyword>
  <keyword>thrombolysis</keyword>
  <keyword>alteplase</keyword>
  <keyword>tPA</keyword>
  <keyword>EPITHET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasminogen</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

